An investigational GLP-1 and glucagon receptor dual agonist in clinical development for obesity and metabolic liver disease. This record separates established identity and source-linked research context from protocol or commercial fields that are not yet supportable.
FEMETRIC RECORD · PUBLICSurvodutide
Weight ManagementAppetiteFat Loss
Status
Clinical Development
Related
4
Sources
1
UPDATED 2026-09-13
01
Protocol references
SOURCE-LINKED
PUBLISHED STUDY
Source-linked research context
No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.
Route
Subcutaneous
Frequency
See indexed source
Duration
Not indexed
Escalation
Not established
Stage detail pending source extractionStarting and target doses are indexed. Intermediate steps are intentionally not inferred.
PUBLISHED STUDYThe Lancet Diabetes & Endocrinology, 2024Verified 2026-09-13
Survodutide activates GLP-1 and glucagon receptors. Human phase 2 studies used source-defined escalation and maintenance periods that should not be simplified into a universal schedule.
Mechanism summaries are stored with field-level source provenance for editorial audit.
07
Related research goals
08
Related peptides
01PEPTIDE
Retatrutide
An investigational GIP, GLP-1 and glucagon receptor agonist studied for obesity and metabolic outcomes.
Weight ManagementAppetiteGlucose / Insulin
02PEPTIDE
Mazdutide
A GLP-1 and glucagon receptor dual agonist studied in obesity and type 2 diabetes, with development and regulatory status varying by region.
Weight ManagementGlucose / InsulinFat Loss
03PEPTIDE
Pemvidutide
An investigational GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Weight ManagementFat LossBody Composition
04PEPTIDE
Tirzepatide
An approved dual GIP and GLP-1 receptor agonist studied across type 2 diabetes, obesity and cardiometabolic outcomes.